What Does AnaptysBio (ANABV) Do? — Complete Guide to Its Stock Outlook, Earnings, Market Cap, Peers, and Headquarters
AnaptysBio is an immunology-focused biotechnology company that earns royalties from GSK’s blockbuster therapy Jemperli. Through a 2026 spin-off of its drug development business, it aims to maximize corporate value by separating into a stable cash-generating entity and a high-growth development company.
Subscribe🏢 What kind of company is AnaptysBio?
AnaptysBio Inc (ANABV) is a clinical-stage biotechnology company headquartered in San Diego, California. It has developed innovative antibody-based drug candidates designed to modulate the human immune system and treat atopic dermatitis, asthma, and various inflammatory diseases. Its biggest catalyst in 2026 is a major corporate spin-off. The company will separate its drug development operations into a newly listed company called First Tracks Biotherapeutics (TRAX), while the existing AnaptysBio (ANAB) will remain a holding company that manages the recurring royalty income generated through partnerships with GSK and others, including Jemperli. The currently traded ANABV shares reflect rights immediately before the spin-off and therefore have a temporary when-issued ticker designation.
💰 How does it make money?
| Business segment | Revenue share | Description |
|---|---|---|
| Collaboration and royalty revenue | Approximately 100% | Milestone payments and royalties based on antibody technologies received from GSK, including Jemperli, and other partners |
AnaptysBio’s revenue currently comes entirely from royalties and milestone payments tied to the commercial success of antibody-based drugs whose technologies it previously licensed. In particular, royalties received by AnaptysBio have risen sharply as sales of GSK’s endometrial cancer treatment Jemperli have accelerated. Once the spin-off is completed in 2026, existing ANAB is expected to transform into a cash-generative company that returns its royalty income—projected to reach hundreds of millions of dollars annually through 2029—to shareholders through dividends or share repurchases.
I don't see any leaked Chinese characters in the sentence you provided. The sentence "Market cap and company size" contains only English text. If you intended to share a different sentence that contains Chinese characters, or if you'd like me to review the HTML formatting, please let me know. The current sentence appears to be clean English with appropriate HTML heading tags and an emoji.Its market capitalization is $1.9B, equivalent to approximately About 1% of Samsung Electronics’ market cap. It has - employees.
AnaptysBio is a biopharmaceutical company with a market capitalization of $1.9B, approximately About 1% of Samsung Electronics’ market cap. Around - research professionals have led its drug development efforts, which will move to TRAX in the future. After the spin-off, financial stability and drug-development risk will be fully separated into two companies, providing investors with distinct investment choices.
📈 AnaptysBio outlook and stock performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangeIts future prospects should be assessed according to the two companies’ distinct business models following the spin-off. In 2025, royalty revenue from drugs such as Jemperli increased sharply, allowing the company to return to profitability in the fourth quarter. The surviving AnaptysBio is expected to maximize -, supported by a stable - and dependable cash flow, and has announced a $100 million share repurchase program. By contrast, newly listed First Tracks will follow the path of a typical high-risk, high-reward biotechnology company, using the $180 million in cash it has secured—equivalent to roughly two years of operating funding—to achieve clinical breakthroughs in its atopic dermatitis and asthma pipeline.
⚔️ Key competitive advantages and risks
The company has adopted a strategic spin-off designed to maximize investment value by separating drug-development uncertainty from reliable royalty income.
💪 Key competitive advantages
⚠️ Key risks
🔄 Competitors and related stocks
AnaptysBio’s drug development business competes with global industry leaders developing treatments for immune-mediated diseases, including Sanofi/Regeneron, which owns Dupixent, AbbVie (ABBV), and Roivant Sciences (ROIV). Meanwhile, the surviving company’s royalty-management structure can be compared with special-purpose financial and biotechnology holding companies such as Royalty Pharma (RPRX) and Ligand Pharmaceuticals (LGND) in terms of its revenue model.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $781.49 | -1.5% | $80.5B | 19.3 | 2.5 | 14.04% | 0.5% |
| ABBV | Abbvie Inc | $257.12 | +0.8% | $454.4B | 72.7 | - | 15221.82% | 2.67% |
| ROIV | Roivant Sciences Ltd | $40.82 | -0.3% | $29.5B | - | 7.0 | -6.21% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| RPRX | Royalty Pharma plc | $58.61 | -0.2% | $33.7B | 31.2 | 3.8 | 12.36% | 1.76% |
 LGND | Ligand Pharmaceuticals Inc | $284.47 | -1.6% | $5.7B | 30.4 | 5.9 | 21.96% | - |
| GSK | GSK Plc ADR | $48.13 | +0.0% | $96.4B | 15.2 | 4.2 | 29.69% | 3.89% |
✅ Investor checklist
Investors should review the following key indicators before investing in AnaptysBio ahead of its major corporate spin-off.
| Checkpoint | What to monitor | Current status |
|---|---|---|
| 📅 Completion of spin-off schedule | Confirm that the planned spin-off and listing of First Tracks (TRAX), scheduled for around the end of April 2026, is completed successfully. | In progress |
| 💰 Jemperli sales performance | Check whether sales of GSK’s Jemperli, the company’s most important source of cash flow, meet market expectations and continue to rise. | Healthy |
| 🧪 Key pipeline clinical data | Monitor Phase 2 and Phase 3 clinical data for major drug candidates in areas such as atopic dermatitis that will transfer to the newly formed company. | Caution |
Immediately before and after the spin-off, institutional investors may conduct significant buying and selling, or rebalancing, as they establish appropriate valuations for the parent and subsidiary companies. As a result, short-term stock-price volatility could be substantial.
AnaptysBio has entered a harvest period in which the results of years of research are converting into substantial cash flow. By undertaking a bold spin-off to separate risk, it offers an interesting case for both investors seeking stable dividends and those pursuing substantial gains from successful drug development.
View AnaptysBio’s real-time price, technical indicators, and peer comparisons at a glance on US Stock Today’s real-time dashboard.
Subscribe Today's 5 AI picks, all free